

Attorney's Docket No.: 12804-027001

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bernard Moss et al.

Art Unit: 1645

Serial No.: 10/646,628

Examiner: R. Zeman

Filed

: August 22, 2003

Title

: MVA EXPRESSING MODIFIED HIV ENVELOPE, GAG, AND POL GENES

## MAIL STOP AMENDMENT

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT

Applicants request consideration of the references listed on the attached PTO-1449 form. Under 37 C.F.R. § 1.98 (a)(2)(ii), only copies of foreign patent documents and/or non-patent literature are enclosed. Copies of any listed U.S. patents or U.S. patent application publications ean be provided upon request.

This statement is being filed within before the receipt of a first Office Action on the merits. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: 18 MAY 2005

Anita L/Meiklejohn, Ph.D. Reg. No. 35,283

Fish & Richardson P.C. 225 Franklin St. Boston, MA 02110

Telephone: (617) 542-5070

Facsimile: (617) 542-8906

21087439.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date of Deposit

· · · · ·

Signature

Typed or Printed Name of Person Signing Certificate

Sheet	1	٥f	1	
Sneet	1	10	- 1	

	Substitute Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 12804-027001	Application No. 10/646,628	1
	Information Disclosure Statement by Applicant	Applicant Bernard Moss et al.			
Ž	MAY 2 3 2005 Use several should be several shoul	eets if necessary)	Filing Date August 22, 2003	Group Art Unit 1645	

Comment of the second			U.S. Pate	ent Documents			
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	5,795,577	8/18/1998	Kieny et al.	424	208.1	
* **	AB						

	Foreig	n Patent Doc	uments or P	ublished Foreign	Patent A	Application	าร	
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans Yes	lation No
	AC	WO 99/63098	12/9/1999	WIPO				
	AD	WO 89/12095	12/14/1989	WIPO				
	AE	EP 0 538 496	8/26/1991	EPO				

(	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
	AF	Belyakov et al., "Induction of a Mucosal Cytotoxic T-Lymphocyte Response by" J. of Virology 72(1):8264-8272, 1998.
	AG	Davison et al., "Structure of Vaccinia Virus Early Promoters" J. Mol. Biol. 210:749-769, 1989.
	AH	Hanke et al., "Enhancement of MHC class I-restricted peptide-specific T cell induction" Vaccine 16(5):439-445, 1998.
	AI	Hanke et al., "Lack of toxicity and persistence in the mouse associated with administration of candidate" Vaccine 21:108-114, 2002.
	AJ	Hanke et al., "Development of a DNA-MVA/HIVA vaccine for Kenya" Vaccine 20:1995-1998, 2002.
	AK	Hanke et al., "Pre-clinical development of a mutli-CTL epitope-based DNA prime MVA boost vaccine for AIDS" Immunology Letters 66:177-181, 1999.
	AL	Hanke et al., "Effective induction of HIV-specific CTL by multi-epitope using gene gun" Vaccine 17:589-596, 1999.
	AM	Hanke et al., "Immunogenicities of intravenous and intramuscular administrations of modified vaccinia" J. of General Virology 79:83-90, 1998.
	AN	Haffar et al., "The Carboxy Terminus of Human Immunodeficiency Virus Type I gp160" J. of Virology 64(6):3100-3103, 1990.
	AO	Masternak et al., "cis- and trans-Acting Elements Involved in Reactivation of Vaccinia Virus Early Transcription" J. of Virology 70(12):8737-8746, 1996.
	AP	Wee et al., "A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces" J. of General Virology 83:75-80, 2002.
	AQ	Wyatt et al., "Development of a replication-deficient recombinant vaccinia virus vaccine effective against" Vaccine 14(15):1451-1458, 1996.
	AR	Wyatt et al., "Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective" Vaccine 18:392-397, 2000.

Examiner Signature	Date Considered				
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.					